Malin Parmar's programme to generate dopamine neurons from stem cells has laid groundwork for cell therapy in Parkinson's disease. Parmar's team developed optimised protocols for differentiating iPS and embryonic stem cells into midbrain dopamine neurons with physiological properties matching native substantia nigra neurons—including appropriate neurotransmitter release and electrophysiological responses. Her work emphasises functional validation: the derived neurons must not only express dopamine markers but also demonstrate electrophysiological maturity and appropriate connectivity. Parmar's laboratory has advanced this research toward clinical translation, with allogeneic dopamine neuron products now entering early-stage human trials for Parkinson's disease. A key achievement is demonstrating long-term survival and functional integration of transplanted dopamine neurons in rodent and primate Parkinson's models, with restoration of motor function. Her research addresses fundamental questions about neuronal maturation, engraftment, and circuit integration—challenges that apply broadly to neural cell therapy. Parmar's work has also established standardised protocols for assessing neural cell quality, maturity, and safety, providing benchmarks for regulatory approval. Her translational strategy emphasises rigorous preclinical characterisation before human application, a principle that has elevated the credibility of stem cell neurology. Parmar's contributions position dopamine neuron replacement as a tractable near-term therapeutic goal, with clinical data expected to emerge over the coming years as trial cohorts mature.
Most clinical uses of stem cells remain investigational — check the evidence and approval status for your condition before acting on any clinic's claims.
Sources & profiles
← All pioneers · Conditions compared →